ubmslatePT-logo-ubm

PT Mobile Logo

Search form

Topics:

Brian Miller, MD, PhD, MPH

Brian Miller, MD, PhD, MPH

Dr Miller is Associate Professor in the Department of Psychiatry and Health Behavior at Augusta University in Augusta, GA. Current research focuses on inflammation/cytokines as a potential clinical state and relapse predictive marker in schizophrenia, and is funded by an NIMH K23 Mentored Patient-Oriented Research Career Development Award and the NIH Clinical Loan Repayment Program Award. He has been recognized with several young investigator awards, the 2010 Laughlin Fellowship from the American College of Psychiatrists, and a 2011 Exemplary Psychiatrist Award from the National Alliance on Mental Illness. He is the Schizophrenia Section Editor for Psychiatric Times.

Posts by Author

The results of a phase 3 trial demonstrated significant benefit over placebo.

Recent findings suggest metabolic abnormalities may be independent of the effects of antipsychotics.

What’s the optimal approach for patients with treatment-resistant schizophrenia?

Can dietary supplementation decrease the risk of transition to psychosis?

A recent meta-analysis shows this agent is useful in the prevention and treatment of antipsychotic-induced weight gain.

©Shutterstock

A “high-tech” approach to relapse prevention in patients with schizophrenia.

A recent meta-analysis shows this adjunctive agent reduces residual symptoms of psychopathology as well as body weight.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.